Home › Research › Biomarkers
Head-to-head comparison of brain-derived pTau217 and total pTau217 for brain amyloid and tau pathology classification
Yuanbing Jiang, Wenyue Zheng, Zengjie Xia, Wan Wa Wong, Lily K W Cheng, Fanny C Ip, Siu Man Choi, Andrew L T Chan et al.. Proceedings of the National Academy of Sciences of the United States of America, 2026-03-02
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Phosphorylated-tau 217 (pTau217) is currently the most promising blood-based biomarker for accurately detecting Alzheimer's disease (AD) pathology. However, interference from peripheral tau species in the kidneys or peripheral nerves can hinder diagnostic precision. Recently developed brain-derived pTau217 (BD-pTau217) assays emerge as highly specific tools for detecting AD-related pathological changes in the brain. In this study, we conducted a head-to-head comparison of the NULISAqpcr BD-pTau217 assay and Simoa ALZpath total p-Tau217 assay in two independent, amyloid-PET-characterized Chinese cohorts. Our results demonstrate a strong correlation between BD-pTau217 and total pTau217 (ρ = 0.89 to 0.90), with BD-pTau217 showing significantly reduced interference from kidney dysfunction, as evidenced by weaker associations with blood levels of urea (ρBD-pTau217 = 0.02 to 0.06, ρTotal-pTau217 = 0.06 to 0.12) and creatinine (ρBD-pTau217 = 0.03 to 0.08, ρTotal-pTau217 = 0.16 to 0.18). Moreover, BD-pTau217 is more strongly associated with amyloid-PET Centiloid values (ρBD-pTau217 = 0.78 to 0.80, ρTotal-pTau217 = 0.74 to 0.77) and exhibits superior classification performance for amyloid-β (Aβ) pathology (area under the curve [AUC]BD-pTau217 = 0.96 to 0.98, AUCTotal-pTau217 = 0.94 to 0.97). Furthermore, BD-pTau217 outperforms total pTau217 for identifying tau-positive individuals within the Aβ-positive group (AUCBD-pTau217 = 0.89, AUCTotal-pTau217 = 0.78), facilitating more accurate disease staging. These findings underscore BD-pTau217 as a highly sensitive and specific blood-based biomarker for AD that has significant potential for early detection, precise classification, and staging of AD-related brain pathology in clinical practice.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jiang, Y., Zheng, W., Xia, Z., Wong, W. W., Cheng, L. K. W., Ip, F. C., et al. (2026). Head-to-head comparison of brain-derived pTau217 and total pTau217 for brain amyloid and tau pathology classification. Proceedings of the National Academy of Sciences of the United States of America. https://doi.org/10.1073/pnas.2536792123
Vancouver
Jiang Y, Zheng W, Xia Z, Wong WW, Cheng LKW, Ip FC, et al. Head-to-head comparison of brain-derived pTau217 and total pTau217 for brain amyloid and tau pathology classification. Proceedings of the National Academy of Sciences of the United States of America. 2026. doi:10.1073/pnas.2536792123. PMID: 41770931.
BibTeX
@article{jiang2026-41770931,
author = {Jiang, Yuanbing and Zheng, Wenyue and Xia, Zengjie and Wong, Wan Wa and Cheng, Lily K W and Ip, Fanny C and Choi, Siu Man and Chan, Andrew L T and others},
title = {{Head-to-head comparison of brain-derived pTau217 and total pTau217 for brain amyloid and tau pathology classification}},
journal = {Proceedings of the National Academy of Sciences of the United States of America},
year = {2026},
doi = {10.1073/pnas.2536792123},
pmid = {41770931},
url = {https://doi.org/10.1073/pnas.2536792123}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Our results demonstrate a strong correlation between BD-pTau217 and total pTau217 (ρ = 0.89 to 0.90), with BD-pTau217 showing significantly reduced interference from kidney dysfunction, as evidenced by weaker associations with blood levels of urea (ρBD-pTau217 = 0.02 to 0.06, ρTotal-pTau217 = 0.06 to 0.12) and creatinine (ρBD-pTau217 = 0.03 to 0.08, ρTotal-pTau217 = 0.16 to 0.18).
- Moreover, BD-pTau217 is more strongly associated with amyloid-PET Centiloid values (ρBD-pTau217 = 0.78 to 0.80, ρTotal-pTau217 = 0.74 to 0.77) and exhibits superior classification performance for amyloid-β (Aβ) pathology (area under the curve [AUC]BD-pTau217 = 0.96 to 0.98, AUCTotal-pTau217 = 0.94 to 0.97).
- These findings underscore BD-pTau217 as a highly sensitive and specific blood-based biomarker for AD that has significant potential for early detection, precise classification, and staging of AD-related brain pathology in clinical practice.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 25 of the 56 points we could judge it on, which is 45 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Proceedings of the National Academy of Sciences of the United States of America) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41770931) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 25 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 25 of the 56 points we could judge it on is 45 out of 100. |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.